

Title (en)

ACYL SULFONAMIDES THAT ARE BCL FAMILY ANTAGONISTS FOR USE IN CLINICAL MANAGEMENT OF CONDITIONS CAUSED OR MEDIATED BY SENESCENT CELLS AND FOR TREATING CANCER

Title (de)

ACYLSULFONAMIDE ALS ANTAGONISTEN DER BCL-FAMILIE ZUR VERWENDUNG BEIM KLINISCHEN MANAGEMENT VON ERKRANKUNGEN, DIE DURCH SENESZENTE ZELLEN VERURSACHT ODER VERMITTELT WERDEN, SOWIE ZUR BEHANDLUNG VON KREBS

Title (fr)

ACYLSULFONAMIDES À TITRE D'ANTAGONISTES DE LA FAMILLE BCL DESTINÉS À ÊTRE UTILISÉS DANS LA GESTION CLINIQUE D'ÉTATS PATHOLOGIQUES PROVOQUÉS OU INDUITS PAR DES CELLULES SÉNESCENTES AINSI QUE DANS LE TRAITEMENT DU CANCER

Publication

EP 3807245 B1 20231025 (EN)

Application

EP 19819804 A 20190613

Priority

- US 2019037067 W 20190613
- US 201862684681 P 20180613

Abstract (en)

[origin: WO2019241567A1] The aryl sulfonamide compounds of this invention have powerful and cell-type specific Bcl inhibitory activity. Selected compounds in this class promote apoptosis in senescent cells, and are being developed for treating senescent-related conditions. Selected compounds in this class promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.

IPC 8 full level

C07D 207/337 (2006.01); **A61K 31/675** (2006.01); **A61P 9/10** (2006.01); **A61P 11/00** (2006.01); **A61P 19/02** (2006.01); **A61P 27/00** (2006.01); **A61P 43/00** (2006.01); **C07D 401/12** (2006.01)

CPC (source: AU EP KR US)

A61K 31/496 (2013.01 - KR); **A61K 31/661** (2013.01 - KR); **A61P 9/10** (2018.01 - AU EP US); **A61P 11/00** (2018.01 - AU EP KR US); **A61P 19/02** (2018.01 - AU EP KR); **A61P 27/00** (2018.01 - AU EP US); **A61P 35/00** (2018.01 - KR US); **A61P 43/00** (2018.01 - EP KR); **C07D 207/337** (2013.01 - AU); **C07D 207/34** (2013.01 - EP); **C07D 207/36** (2013.01 - KR); **C07D 401/10** (2013.01 - US); **C07D 401/12** (2013.01 - AU EP KR US); **C07D 401/14** (2013.01 - US); **C07D 403/10** (2013.01 - US); **C07F 9/09** (2013.01 - KR); **C07F 9/650952** (2013.01 - US); **C07F 9/65583** (2013.01 - EP); **A61P 43/00** (2018.01 - AU)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2019241567 A1 20191219; AU 2019287528 A1 20210128; AU 2024219624 A1 20241003; CA 3101878 A1 20191219; CN 112469696 A 20210309; EP 3807245 A1 20210421; EP 3807245 A4 20210707; EP 3807245 B1 20231025; EP 4335516 A2 20240313; EP 4335516 A3 20240501; ES 2965890 T3 20240417; JP 2021528392 A 20211021; JP 2023085268 A 20230620; KR 102520382 B1 20230411; KR 20210020930 A 20210224; US 10981892 B2 20210420; US 2020199103 A1 20200625; US 2020317640 A1 20201008; US 2020354336 A9 20201112; US 2022017485 A1 20220120

DOCDB simple family (application)

US 2019037067 W 20190613; AU 2019287528 A 20190613; AU 2024219624 A 20240911; CA 3101878 A 20190613; CN 201980037878 A 20190613; EP 19819804 A 20190613; EP 23205232 A 20190613; ES 19819804 T 20190613; JP 2020569185 A 20190613; JP 2023034166 A 20230307; KR 20207036888 A 20190613; US 201816636299 A 20180813; US 202016897905 A 20200610; US 202117338368 A 20210603